JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB177835

Human Anti-Chikungunya Virus IgG ELISA Kit

Be the first to review this product! Submit a review

|

(10 Publications)

Human Anti-Chikungunya Virus IgG ELISA Kit is an indirect ELISA for the qualitative detection of IgG class antibodies against Chikungunya Virus in human plasma and serum samples.

- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation
- Cut-off, positive and negative controls included

Key facts

Detection method

Colorimetric

Sample types

Citrate plasma, Heparin Plasma, Serum

Reacts with

Human

Assay type

Sandwich (qualitative)

Assay Platform

Microplate

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Abcam's anti-Chikungunya Virus IgG Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgG class antibodies against Chikungunya Virus in Human serum and plasma.

A 96-well plate has been precoated with anti-Human antibodies to bind to corresponding antibodies of the sample. Controls or test samples are added to the wells and incubated. Following washing, the Chikungunya Virus antigen is added to the wells and incubated. The wells are then washed as before and the biotinylated Chikungunya Virus antibodies are added to each well followed by incubation. After a last wash step, the streptavidin peroxidase (SP) conjugate which binds to the biotinylated Chikungunya Virus-specific antibodies is added to the wells. TMB is then catalyzed by the SP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Chikungunya Virus IgG sample captured in plate.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Precision

[ { "reproducibilityType": "Inter", "sample": "High + Serum", "replicates": 3, "mean": null, "standardDeviation": null, "coefficientOfVariability": "3.7" }, { "reproducibilityType": "Inter", "sample": "Low + Serum", "replicates": 3, "mean": null, "standardDeviation": null, "coefficientOfVariability": "10.9" }, { "reproducibilityType": "Intra", "sample": "Low + Serum", "replicates": 23, "mean": null, "standardDeviation": null, "coefficientOfVariability": "9.4" }, { "reproducibilityType": "Intra", "sample": "High + Serum", "replicates": 24, "mean": null, "standardDeviation": null, "coefficientOfVariability": "2.7" } ]

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab177835-1x96Tests", "assetComponentDetails": [ { "size":"1 x 2 mL", "name":"Chikungunya Virus IgG Cut-off Control", "number":"AB177835-CMP05", "productcode":"" }, { "size":"1 x 1.5 mL", "name":"Chikungunya Virus IgG Positive Control", "number":"AB177835-CMP07", "productcode":"" }, { "size":"1 x 6 mL", "name":"Chikungunya Virus biotinylated antibody Solution 2", "number":"AB177835-CMP10", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Strip holder", "number":"AB177835-CMP13", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Anti-Human (IgG) Coated Microplate (12 x 8 wells)", "number":"AB177835-CMP08", "productcode":"" }, { "size":"1 x 1 Unit", "name":"Cover Foil", "number":"AB177835-CMP01", "productcode":"" }, { "size":"1 x 6 mL", "name":"Streptavidin Conjugate", "number":"AB177835-CMP11", "productcode":"" }, { "size":"1 x 100 mL", "name":"IgG Sample Diluent", "number":"AB177835-CMP02", "productcode":"" }, { "size":"1 x 6 Vial", "name":"Chikungunya Virus antigen Solution 1 (Lyophilized)", "number":"AB177835-CMP09", "productcode":"" }, { "size":"1 x 15 mL", "name":"TMB Substrate Solution", "number":"AB177835-CMP03", "productcode":"" }, { "size":"1 x 50 mL", "name":"20X Washing Solution", "number":"AB177835-CMP04", "productcode":"" }, { "size":"1 x 15 mL", "name":"Stop Solution", "number":"AB177835-CMP12", "productcode":"" }, { "size":"1 x 1.5 mL", "name":"Chikungunya Virus IgG Negative Control", "number":"AB177835-CMP06", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
+4°C

Product protocols

Target data

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Tropical medicine and infectious disease 8: PubMed37104340

2023

Clinical Diagnosis of Chikungunya Infection: An Essential Aid in a Primary Care Setting Where Serological Confirmation Is Not Available.

Applications

Unspecified application

Species

Unspecified reactive species

Juan C Rueda,Ingris Peláez-Ballestas,Jose-Ignacio Angarita,Ana M Santos,Carlos Pinzon,Eugenia-Lucia Saldarriaga,Jorge M Rueda,Elias Forero,Diego L Saaibi,Paula X Pavía,Marta Juliana Mantilla,Gustavo Rodríguez-Salas,Juan Camilo Santacruz,Igor Rueda,Mario H Cardiel,John Londono

Transboundary and emerging diseases 69:e895-e905 PubMed34752688

2021

Can presence of HLA type I and II alleles be associated with clinical spectrum of CHIKV infection?

Applications

Unspecified application

Species

Unspecified reactive species

Juan C Rueda,Ana M Santos,Jose-Ignacio Angarita,Eugenia-Lucia Saldarriaga,Ingris Peláez-Ballestas,Alejandro Silva Espinosa,Ignacio Briceño-Balcázar,Sofia Arias-Correal,Jose Arias-Correal,Catalina Villota-Erazo,Viviana Reyes,Santiago Bernal-Macías,Mario H Cardiel,John Londono

Virology journal 18:190 PubMed34544442

2021

Detection of chikungunya virus in the Southern region, Saudi Arabia.

Applications

Unspecified application

Species

Unspecified reactive species

Abdulrahim R Hakami,Abdullah A Alshamrani,Mohamad Alqahtani,Yasser Alraey,Razan A Alhefzi,Sultan Alasmari,Mohamed Makkawi,Gasim Dobie,Mushtaq Mir,Mohamed Alshahrani,Ayed Dera,Mohammed Alfaifi,Mesfer Al Shahrani,Ahmad Matari,Ali Essa Asiry

Nature communications 12:4636 PubMed34330906

2021

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.

Applications

Unspecified application

Species

Unspecified reactive species

Pedro M Folegatti,Kate Harrison,Lorena Preciado-Llanes,Fernando Ramos Lopez,Mustapha Bittaye,Young Chan Kim,Amy Flaxman,Duncan Bellamy,Rebecca Makinson,Jonathan Sheridan,Sasha R Azar,Rafael Kroon Campos,Mark Tilley,Nguyen Tran,Daniel Jenkin,Ian Poulton,Alison Lawrie,Rachel Roberts,Eleanor Berrie,Shannan L Rossi,Adrian Hill,Katie J Ewer,Arturo Reyes-Sandoval

The American journal of tropical medicine and hygiene 104:1438-1443 PubMed33617471

2021

Age-Dependent Evaluation of Immunoglobulin G Response after Chikungunya Virus Infection.

Applications

Unspecified application

Species

Unspecified reactive species

Harshad P Patil,Mrunal Gosavi,Akhilesh C Mishra,Vidya A Arankalle

JCI insight 5: PubMed32155134

2020

Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Kaustuv Nayak,Vineet Jain,Manpreet Kaur,Naushad Khan,Kamalvishnu Gottimukkala,Charu Aggarwal,Rohit Sagar,Shipra Gupta,Ramesh Chandra Rai,Kritika Dixit,Mohammad Islamuddin,Wajihul Hasan Khan,Anil Verma,Deepti Maheshwari,Yadya M Chawla,Elluri Seetharami Reddy,Harekrushna Panda,Pragati Sharma,Priya Bhatnagar,Prabhat Singh,Siva Raghavendhar B,Ashok Kumar Patel,Vinod H Ratageri,Anmol Chandele,Pratima Ray,Kaja Murali-Krishna

Emerging microbes & infections 8:1490-1500 PubMed31631794

2019

Demographic and clinical characteristics of chikungunya patients from six Colombian cities, 2014-2015.

Applications

Unspecified application

Species

Unspecified reactive species

Juan C Rueda,Ana M Santos,Jose-Ignacio Angarita,Rodrigo B Giraldo,Eugenia-Lucia Saldarriaga,Jesús Giovanny Ballesteros Muñoz,Elías Forero,Hugo Valencia,Francisco Somoza,Daniel Martin-Arsanios,Elias-Josué Quintero,Viviana Reyes-Martinez,Diana Padilla,Francy M Cuervo,Ingris Peláez-Ballestas,Mario H Cardiel,Paula X Pavía,John Londono

Viruses 11: PubMed31052472

2019

Development of an E2 ELISA Methodology to Assess Chikungunya Seroprevalence in Patients from an Endemic Region of Mexico.

Applications

Unspecified application

Species

Unspecified reactive species

Young Chan Kim,César López-Camacho,Nallely Garcia-Larragoiti,Alan Cano-Mendez,Karina Guadalupe Hernandez-Flores,Carlos Alonso Domínguez-Alemán,Maria Antonieta Mar,Héctor Vivanco-Cid,Martha Eva Viveros-Sandoval,Arturo Reyes-Sandoval

PLoS neglected tropical diseases 9:e0004119 PubMed26492074

2015

Utilization of an Eilat Virus-Based Chimera for Serological Detection of Chikungunya Infection.

Applications

Unspecified application

Species

Unspecified reactive species

Jesse H Erasmus,James Needham,Syamal Raychaudhuri,Michael S Diamond,David W C Beasley,Stan Morkowski,Henrik Salje,Ildefonso Fernandez Salas,Dal Young Kim,Ilya Frolov,Farooq Nasar,Scott C Weaver

PLoS neglected tropical diseases 9:e0003684 PubMed25905779

2015

A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.

Applications

WB

Species

Human

Christopher Weber,Sarah M Büchner,Barbara S Schnierle
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com